protein phosphatase 2a pp2a inhibitor endothall (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
94
Structured Review
MedChemExpress
protein phosphatase 2a pp2a inhibitor endothall
Protein Phosphatase 2a Pp2a Inhibitor Endothall, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pp2a/Endothall/pm41827042-45-8-17
Average 94 stars, based on 2 article reviews
Protein Phosphatase 2a Pp2a Inhibitor Endothall, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pp2a/Endothall/pm41827042-45-8-17
Average 94 stars, based on 2 article reviews
protein phosphatase 2a pp2a inhibitor endothall - by Bioz Stars,
2026-11
94/100 stars
Images
Related Articles
Cell Culture:Article Title: SPNS2 exports sphingosine-1-phosphate and imports glucose Article Snippet: .. Cells were seeded (200,000 cells/6-well) and 24 h later, the cell culture medium was replaced with glucose-free DMEM (Gibco, # A14430-01, phenol-red and glucose-free) with 10% FBS, 1 mM sodium pyruvate, and 1 × GlutaMax for 4 h. The medium was then replaced by DMEM without or with 1 g/L or 4.5 g/L glucose (#G8644, Sigma) for 24 h. In other experiments, cells were treated with 200 μM of the S1P lyase inhibitor A6770 (#29972, Cayman Chemical Company), 2 μM of the SPNS2 inhibitor SLF1081851 (#HY-149004, MedChemExpress), or the corresponding vehicles in medium with 4.5 g/L glucose for 24 h. Where indicated, cells were treated with 500 nM or 10 μM S1P (#860492, Avanti Polar Lipids) for 30 min, 100 nM insulin (#C-52310, PromoCell) for 4 h, 10 nM BAY-876 (#HY-100017, MedChemExpress) for 4 h, or with 1 μM LB-100 (#HY-18597, MedChemExpress), 10 μM DT-061 (#HY-112929, MedChemExpress), 2 nM Calyculin A (#HY-18983, MedChemExpress), or 100 nM Article Title: SPNS2 exports sphingosine-1-phosphate and imports glucose. Article Snippet: Transfections were carried out as described above, while SPNS2 CRISPR/Cas9 KO Plasmids were transfected in the presence of 5 μM L-755,507 (#sc-204045, Santa Cruz Biotechnology). .. In vitro cell treatments Cells were seeded (200,000 cells/6-well) and 24 h later, the cell culture medium was replaced with glucose-free DMEM (Gibco, # A14430-01, phenol-red and glucose free) with 10% FBS, 1 mM sodium pyruvate, and 1X GlutaMax for 4 h. The medium was then replaced by DMEM without or with 1 g/L or 4.5 g/L glucose (#G8644, Sigma) for 24 h. In other experiments, cells were treated with 200 μM of the S1P lyase inhibitor A6770 (#29972, Cayman Chemical Company), 2 μM of the SPNS2 inhibitor SLF1081851 (#HY-149004, MedChemExpress), or the corresponding vehicles in medium with 4.5 g/L glucose for 24 h. Where indicated, cells were treated with 500 nM or 10 μM S1P (#860492, Avanti Polar Lipids) for 30 min, 100 nM insulin (#C-52310, PromoCell) for 4 h, 10 nM BAY-876 (#HY-100017, MedChemExpress) for 4 h, or with 1 μM LB-100 (#HY-18597, MedChemExpress), 10 μM DT-061 (#HY-112929, MedChemExpress), 2 nM Calyculin A (#HY-18983, MedChemExpress), or 100 nM Endothall AR TI CL E IN Recombinant:Article Title: SENP5 enhances antiviral innate immunity by promoting AURKA-dependent STAT2 phosphorylation Article Snippet: .. Recombinant human interferon α-2a, AURKA inhibitor (Alisertib) and Article Title: SENP5 enhances antiviral innate immunity by promoting AURKA-dependent STAT2 phosphorylation. Article Snippet: .. Recombinant human interferon α-2a, AURKA inhibitor (Alisertib) and In Vitro:Article Title: SPNS2 exports sphingosine-1-phosphate and imports glucose. Article Snippet: Transfections were carried out as described above, while SPNS2 CRISPR/Cas9 KO Plasmids were transfected in the presence of 5 μM L-755,507 (#sc-204045, Santa Cruz Biotechnology). .. In vitro cell treatments Cells were seeded (200,000 cells/6-well) and 24 h later, the cell culture medium was replaced with glucose-free DMEM (Gibco, # A14430-01, phenol-red and glucose free) with 10% FBS, 1 mM sodium pyruvate, and 1X GlutaMax for 4 h. The medium was then replaced by DMEM without or with 1 g/L or 4.5 g/L glucose (#G8644, Sigma) for 24 h. In other experiments, cells were treated with 200 μM of the S1P lyase inhibitor A6770 (#29972, Cayman Chemical Company), 2 μM of the SPNS2 inhibitor SLF1081851 (#HY-149004, MedChemExpress), or the corresponding vehicles in medium with 4.5 g/L glucose for 24 h. Where indicated, cells were treated with 500 nM or 10 μM S1P (#860492, Avanti Polar Lipids) for 30 min, 100 nM insulin (#C-52310, PromoCell) for 4 h, 10 nM BAY-876 (#HY-100017, MedChemExpress) for 4 h, or with 1 μM LB-100 (#HY-18597, MedChemExpress), 10 μM DT-061 (#HY-112929, MedChemExpress), 2 nM Calyculin A (#HY-18983, MedChemExpress), or 100 nM Endothall AR TI CL E IN |
